Skip to main content
Journal cover image

Clinical Outcomes and Bacterial Characteristics of Carbapenem-resistant Acinetobacter baumannii Among Patients From Different Global Regions.

Publication ,  Journal Article
Wang, M; Ge, L; Chen, L; Komarow, L; Hanson, B; Reyes, J; Cober, E; Alenazi, T; Zong, Z; Xie, Q; Liu, Z; Li, L; Yu, Y; Gao, H; Kanj, SS ...
Published in: Clin Infect Dis
February 17, 2024

BACKGROUND: Carbapenem-resistant Acinetobacter baumannii (CRAb) is 1 of the most problematic antimicrobial-resistant bacteria. We sought to elucidate the international epidemiology and clinical impact of CRAb. METHODS: In a prospective observational cohort study, 842 hospitalized patients with a clinical CRAb culture were enrolled at 46 hospitals in five global regions between 2017 and 2019. The primary outcome was all-cause mortality at 30 days from the index culture. The strains underwent whole-genome analysis. RESULTS: Of 842 cases, 536 (64%) represented infection. By 30 days, 128 (24%) of the infected patients died, ranging from 1 (6%) of 18 in Australia-Singapore to 54 (25%) of 216 in the United States and 24 (49%) of 49 in South-Central America, whereas 42 (14%) of non-infected patients died. Bacteremia was associated with a higher risk of death compared with other types of infection (40 [42%] of 96 vs 88 [20%] of 440). In a multivariable logistic regression analysis, bloodstream infection and higher age-adjusted Charlson comorbidity index were independently associated with 30-day mortality. Clonal group 2 (CG2) strains predominated except in South-Central America, ranging from 216 (59%) of 369 in the United States to 282 (97%) of 291 in China. Acquired carbapenemase genes were carried by 769 (91%) of the 842 isolates. CG2 strains were significantly associated with higher levels of meropenem resistance, yet non-CG2 cases were over-represented among the deaths compared with CG2 cases. CONCLUSIONS: CRAb infection types and clinical outcomes differed significantly across regions. Although CG2 strains remained predominant, non-CG2 strains were associated with higher mortality. Clinical Trials Registration. NCT03646227.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Infect Dis

DOI

EISSN

1537-6591

Publication Date

February 17, 2024

Volume

78

Issue

2

Start / End Page

248 / 258

Location

United States

Related Subject Headings

  • beta-Lactamases
  • Prospective Studies
  • Microbiology
  • Microbial Sensitivity Tests
  • Humans
  • Carbapenems
  • Bacterial Proteins
  • Anti-Bacterial Agents
  • Acinetobacter baumannii
  • Acinetobacter Infections
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Wang, M., Ge, L., Chen, L., Komarow, L., Hanson, B., Reyes, J., … Multi-Drug Resistant Organism Network Investigators, . (2024). Clinical Outcomes and Bacterial Characteristics of Carbapenem-resistant Acinetobacter baumannii Among Patients From Different Global Regions. Clin Infect Dis, 78(2), 248–258. https://doi.org/10.1093/cid/ciad556
Wang, Minggui, Lizhao Ge, Liang Chen, Lauren Komarow, Blake Hanson, Jinnethe Reyes, Eric Cober, et al. “Clinical Outcomes and Bacterial Characteristics of Carbapenem-resistant Acinetobacter baumannii Among Patients From Different Global Regions.Clin Infect Dis 78, no. 2 (February 17, 2024): 248–58. https://doi.org/10.1093/cid/ciad556.
Wang M, Ge L, Chen L, Komarow L, Hanson B, Reyes J, et al. Clinical Outcomes and Bacterial Characteristics of Carbapenem-resistant Acinetobacter baumannii Among Patients From Different Global Regions. Clin Infect Dis. 2024 Feb 17;78(2):248–58.
Wang, Minggui, et al. “Clinical Outcomes and Bacterial Characteristics of Carbapenem-resistant Acinetobacter baumannii Among Patients From Different Global Regions.Clin Infect Dis, vol. 78, no. 2, Feb. 2024, pp. 248–58. Pubmed, doi:10.1093/cid/ciad556.
Wang M, Ge L, Chen L, Komarow L, Hanson B, Reyes J, Cober E, Alenazi T, Zong Z, Xie Q, Liu Z, Li L, Yu Y, Gao H, Kanj SS, Figueroa J, Herc E, Cordova E, Weston G, Ananth Tambyah P, Garcia-Diaz J, Kaye KS, Dhar S, Munita JM, Salata RA, Vilchez S, Stryjewski ME, Villegas Botero MV, Iovleva A, Evans SR, Baum K, Hill C, Kreiswirth BN, Patel R, Paterson DL, Arias CA, Bonomo RA, Chambers HF, Fowler VG, Satlin MJ, van Duin D, Doi Y, Multi-Drug Resistant Organism Network Investigators. Clinical Outcomes and Bacterial Characteristics of Carbapenem-resistant Acinetobacter baumannii Among Patients From Different Global Regions. Clin Infect Dis. 2024 Feb 17;78(2):248–258.
Journal cover image

Published In

Clin Infect Dis

DOI

EISSN

1537-6591

Publication Date

February 17, 2024

Volume

78

Issue

2

Start / End Page

248 / 258

Location

United States

Related Subject Headings

  • beta-Lactamases
  • Prospective Studies
  • Microbiology
  • Microbial Sensitivity Tests
  • Humans
  • Carbapenems
  • Bacterial Proteins
  • Anti-Bacterial Agents
  • Acinetobacter baumannii
  • Acinetobacter Infections